Chuang Yi Biotech Past Earnings Performance
Past criteria checks 0/6
Chuang Yi Biotech's earnings have been declining at an average annual rate of -2.2%, while the Pharmaceuticals industry saw earnings growing at 18.5% annually. Revenues have been declining at an average rate of 2.9% per year.
Key information
-2.2%
Earnings growth rate
-1.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 18.5% |
| Revenue growth rate | -2.9% |
| Return on equity | -25.5% |
| Net Margin | -13.6% |
| Last Earnings Update | 30 Jun 2022 |
Revenue & Expenses BreakdownBeta
How Chuang Yi Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 252 | -34 | 97 | 4 |
| 31 Mar 22 | 257 | -33 | 98 | 3 |
| 31 Dec 21 | 261 | -32 | 99 | 3 |
| 30 Sep 21 | 235 | 15 | 101 | 2 |
| 30 Jun 21 | 209 | 61 | 103 | 1 |
| 31 Mar 21 | 194 | 65 | 98 | 1 |
| 31 Dec 20 | 179 | 70 | 93 | 1 |
| 30 Sep 20 | 101 | -105 | 95 | 4 |
| 30 Jun 20 | 23 | -279 | 97 | 7 |
| 31 Mar 20 | 49 | -285 | 114 | 10 |
| 31 Dec 19 | 75 | -290 | 131 | 13 |
| 30 Sep 19 | 193 | -144 | 138 | 13 |
| 30 Jun 19 | 312 | 2 | 146 | 12 |
| 31 Mar 19 | 324 | -1 | 155 | 13 |
| 31 Dec 18 | 336 | -3 | 163 | 13 |
| 30 Sep 18 | 331 | 6 | 158 | 13 |
| 30 Jun 18 | 325 | 15 | 152 | 13 |
| 31 Mar 18 | 283 | 10 | 135 | 15 |
| 31 Dec 17 | 241 | 4 | 118 | 17 |
| 30 Sep 17 | 168 | -24 | 111 | 19 |
| 30 Jun 17 | 94 | -52 | 103 | 21 |
| 31 Mar 17 | 95 | -48 | 100 | 18 |
| 31 Dec 16 | 96 | -44 | 98 | 16 |
| 30 Sep 16 | 98 | -43 | 95 | 17 |
| 30 Jun 16 | 101 | -41 | 93 | 18 |
| 31 Mar 16 | 98 | -38 | 87 | 19 |
| 31 Dec 15 | 94 | -35 | 81 | 19 |
Quality Earnings: 6566 is currently unprofitable.
Growing Profit Margin: 6566 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6566 is unprofitable, and losses have increased over the past 5 years at a rate of 2.2% per year.
Accelerating Growth: Unable to compare 6566's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6566 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-10.2%).
Return on Equity
High ROE: 6566 has a negative Return on Equity (-25.47%), as it is currently unprofitable.